Skip to main content
SpringerLink
Log in

Antidiabetika

  • Chapter
Arzneiverordnungs-Report 2004

  • 73 Accesses

Zusammenfassung

Die Arzneitherapie des Diabetes mellitus hat in den letzten zehn Jahren stetig zugenommen. Die Insulinverordnungen haben sich in diesem Zeitraum mehr als verdoppelt. Die Biguanidverordnungen sind sogar etwa sechsfach angestiegen, während die der Sulfonylharnstoffe annähernd konstant geblieben sind.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 49.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 79.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

Literatur

  • Arzneimittelkommission der deutschen Ärzteschaft (2002): Glaskörper-und Retinablutungen unter Insulin glargin. Dtsch. Ärztebl. 99: C680.

    Google Scholar 

  • Arzneimittelkommission der deutschen Ärzteschaft (2002a): Arzneiverordnungen in der Praxis: Diabetes mellitus.

    Google Scholar 

  • Bailey CJ, Path MRC, Turner RC (1996): Metformin. N Engl J Med 334: 574–579.

    Article  PubMed  CAS  Google Scholar 

  • Berger M, Köbberling J, Windeler J (1996): Wirksamkeit und Wertigkeit der Acarbose. Dtsch Ärztebl 93: B-443–444.

    Google Scholar 

  • Chiasson JL, Josse RG, Hunt JA, Palmason C, Rodger NW et al. (1994): The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. Ann Intern Med 121: 928–935.

    PubMed  CAS  Google Scholar 

  • Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M for the STOP-NIDDM Trail Research Group (2002): Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 359: 2072–2077.

    Article  PubMed  CAS  Google Scholar 

  • Damsbo P, Clausen P, Marbury TC, Windfeld K (1999): A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients. Diabetes Care 22: 789–794.

    Article  PubMed  CAS  Google Scholar 

  • De Fronzo RA, Goodman M (1995): Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 333: 541–549.

    Article  Google Scholar 

  • Diabetes Control and Complications Trial Research Group (1993): The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977–986.

    Article  Google Scholar 

  • Diamant M, Heine RJ (2003): Thiazolidinediones in type 2 diabetes mellitus. Drugs 63:1373–1405.

    Article  PubMed  CAS  Google Scholar 

  • Dills DG, Schneider J (1996): Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Glimepiride/Glyburide Research Group. Horm Metab Res 28:426–429.

    Article  PubMed  CAS  Google Scholar 

  • Draeger KE, Wernicke-Panten K, Lomp H-J, Schüler E, Roßkamp R (1996): Long-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride (Amaryl®): a double-blind comparison with glibenclamide. Horm Metab Res 28:419–425.

    Article  PubMed  CAS  Google Scholar 

  • Dunn CJ, Peters DH (1995): Metformin — A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. Drugs 49: 721–749.

    Article  PubMed  CAS  Google Scholar 

  • Dunn CJ, Plosker GL, Keating GM, McKeage K, Scott LJ (2003): Insulin Glargine. An updated review of its use in the management of diabetes mellitus. Drugs 63: 1743–1778.

    Article  PubMed  CAS  Google Scholar 

  • Everett J, Kerr D (1994): Changing from porcine to human insulin. Drugs 47:286–296.

    Article  PubMed  CAS  Google Scholar 

  • Fisman EZ, Tenenbaum A, Boyko V, Benderly M, Adler Y, Friedensohn A et al. (2001): Oral antidiabetic treatment in patients with coronary disease: time-related increased mortality on combined glyburide/metformin therapy over a 7.7-year follow-up. Clin Cardiol 24: 151–158.

    Article  PubMed  CAS  Google Scholar 

  • Gale EAM for the UK Trial Group (2000): A randomized, controlled trial comparing insulin lispro with human soluble insulin in patients with Type 1 diabetes on intensified insulin therapy. Diabetic Med 17:209–214.

    Article  Google Scholar 

  • Gulliford M, Latinovic R (2004): Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort study. Diabetes Metab Res Rev 20:239–245.

    Article  PubMed  CAS  Google Scholar 

  • Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M (2004): Acarbose reduziert das Risiko für einen Myocardinfarkt bei Typ 2 Diabetikern: Metaanalyse von sieben Langzeitstudien. European Heart Journal 25:10–16.

    Article  PubMed  CAS  Google Scholar 

  • Heinemann L, Heise T (2001): Klinische Wirkungen und Pharmakodynamik der Insulinanaloga lispro, aspart und glargin. Dtsch Med Wschr 126: 597–604.

    Article  PubMed  CAS  Google Scholar 

  • Heinemann L, Linkeschova R, Rave K, Hompesch B, Sedlak M, Heise T (2000): Timeaction profile of the long-acting insulin analog insulin glargine (HOE 901) in comparison with those of NPH insulin and placebo. Diabetes Care 23:644–649.

    Article  PubMed  CAS  Google Scholar 

  • Hollander PA, Zheng H, Schwartz SL, Foley JE, Gatlin MR, Dunning BE, Haas SJ (2001): Importance of early insulin secretion. Comparison of nateglinide and glyburide in previously diet-treated patients with type 2 diabetes. Diabetes Care 24: 983–988.

    Article  PubMed  CAS  Google Scholar 

  • Holman RR, Mayon White V, Orde-Peckar C, Steemson J, Smith B et al. (1983): Prevention of deterioration of renal and sensory-nerve function by more intensive management of insulin-dependent diabetic patients: a two-year randomised prospective study. Lancet: 204–208.

    Google Scholar 

  • Holman RR, Cull CA, Turner RC (1999): A randomized double-blind trial of acarbose in type 2 diabetes shows improved glycemic control over 3 years (U.K). Prospective Diabetes Study 44). Diabetes Care 22: 960–964.

    Article  PubMed  CAS  Google Scholar 

  • Holstein A, Plaschke A, Egberts EH (2001): Lower incidence of severe hypoglycemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide. Diabetes Metab Res Rev 17:467–473.

    Article  PubMed  CAS  Google Scholar 

  • Holstein A, Plaschke A, Hammer C, Egberts EH (2003): Characteristics and time course of severe glimepiride versus glibenclamide-induced hypoglycemia. Eur J Clin Pharmacol 59: 91–97.

    Article  PubMed  CAS  Google Scholar 

  • Home PD, Lindholm A, Riis A (2000): Insulin aspart vs. human insulin in the management of long-term blood glucose control in type 1 diabetes mellitus: a randomized controlled trial. Diabet Med 17: 762–770.

    Article  PubMed  CAS  Google Scholar 

  • Karam JH, Etzwiler DD (eds.) (1983): International Symposium on human insulin. Diabetes Care 6:1–68.

    Google Scholar 

  • Koivisto VA (1998): The human insulin analogue insulin lispro. Ann Med 30:260–266.

    Article  PubMed  CAS  Google Scholar 

  • Lalli C, Ciofetta M, del Sindaco P, Torlone E, Pampanelli S et al. (1999): Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime. Diabetes Care 22: 468–477.

    Article  PubMed  CAS  Google Scholar 

  • Landgraf R, Bilo HJ, Müller PG (1999): A comparison of repaglinide and glibenclamide in the treatment of type 2 diabetic patients previously treated with sulphonylureas. Eur J Clin Pharmacol 55:165–171.

    Article  PubMed  CAS  Google Scholar 

  • Landgraf R, Frank M, Bauer C, Dieken ML (2000): Prandial glucose regulation with repaglinide: its clinical and lifestyle impact in a large cohort of patients with type 2 diabetes. Int J Obes Relat Metab Disord 24(Suppl. 3): S38–S44.

    Article  PubMed  Google Scholar 

  • Langtry HD, Balfour JA (1998): Glimepiride. A review of its use in the management of Type 2 diabetes mellitus. Drugs 55: 563–584.

    Article  PubMed  CAS  Google Scholar 

  • Laube H (2002): Acarbose. An update of its therapeutic use in diabetes treatment. Clin Drug Invest 22:141–156.

    Article  CAS  Google Scholar 

  • Marbury T, Huang WC, Strange P, Lebovitz H (1999): Repaglinide versus glyburide: a one-year comparison trial. Diabetes Res. Clin. Pract. 43:155–166.

    Article  PubMed  CAS  Google Scholar 

  • McCall AL (2001): Clinical review of glimepiride. Expert Opin Pharmacother 2: 699–713.

    Article  PubMed  CAS  Google Scholar 

  • Moses R (2000): A review of clinical experience with the prandial glucose regulator, repaglinide, in the treatment of type 2 diabetes. Expert Opin Pharmacother 1: 1455–1467.

    Article  PubMed  CAS  Google Scholar 

  • Olsson J, Lindberg G, Gottsater M, Lindwall K, Sjostrand A et al. (2000): Increased mortality in type 2 diabetic patients using sulphonylurea and metformin in combination: a population-based observational study. Diabetologia 43: 558–560.

    Article  PubMed  CAS  Google Scholar 

  • Rosenstock J, Samols E, Muchmore DB, Schneider J (1996): Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Glimepiride Study Group. Diabetes Care 19:1194–1199.

    Article  CAS  Google Scholar 

  • Scheen AJ (2003): Is there a role for alpha-Glucosidase inhibitors in the prevention of type 2 diabetes mellitus?. Drugs 63: 933–951.

    Article  PubMed  CAS  Google Scholar 

  • Scheen AJ, Lethiexhe MR, Lefebvre PJ (1999): Minimal influence of the time interval between injection of regulär insulin and food intake on blood glucose control of Type 1 diabetic patients on a basal-bolus insulin scheme. Diabetes Metab 25: 157–162.

    PubMed  CAS  Google Scholar 

  • Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE et al. (2000): Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Brit Med J 321:405–412.

    Article  PubMed  CAS  Google Scholar 

  • Stumvoll M, Nurjhan N, Perriello G, Dailey G, Gerich JE (1995): Metabolie effects of metformin in non-insulin-dependent diabetes mellitus. N Engl J Med 333: 550–554.

    Article  PubMed  CAS  Google Scholar 

  • Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H et al. for the Finnish Diabetes Prevention Study Group (2001): Prevention of type 2 diabetes mellitus by changes in lifestyle among subjeets with impaired glucose tolerance. N Engl J Med 344:1343–1350.

    Article  PubMed  CAS  Google Scholar 

  • UK Prospective Diabetes Study (UKPDS) Group (1998a): Intensive glood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837–853.

    Article  Google Scholar 

  • UK Prospective Diabetes Study (UKPDS) Group (1998b): Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352: 854–865.

    Article  Google Scholar 

  • Veneman TF, Tack CJ, van Haeften TW (1998): The newly developed sulfonylurea glimepiride: a new ingredient, an old reeipe. Neth J Med 52:179–186.

    Article  PubMed  CAS  Google Scholar 

  • Wagstaff AJ, Goa KL (2002): Rosiglitazone: A review of its use in the management of type 2 diabetes. Drugs 62:1805–1837.

    Article  PubMed  CAS  Google Scholar 

  • Wilde MI, McTavish D (1997): Insulin Lispro. A review of its pharmacological properties and therapeutic use in the management of diabetes mellitus. Drugs 54: 597–614.

    Article  PubMed  CAS  Google Scholar 

  • Wolffenbuttel BHR, Landgraf R on behalf of the Dutch and German Repaglinide Study Group (1999): A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Diabetes Care 22: 463–467.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Deutsches Institut für Ernährungsforschung, Arthur-Scheunert-Allee 114-16, 14558, Bergholz-Rehbrücke

    Prof. Dr. med. Dr. rer. nat. Hans-Georg Joost

  2. Höferstraße 15, 68199, Mannheim

    Dr. med. Klaus Mengel

Authors
  1. Prof. Dr. med. Dr. rer. nat. Hans-Georg Joost
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dr. med. Klaus Mengel
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Pharmakologisches Institut der Universität Heidelberg, Im Neuenheimer Feld 366, 69120, Heidelberg

    Ulrich Schwabe

  2. Bachstraße 29, 50858, Köln

    Dieter Paffrath

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Joost, HG., Mengel, K. (2004). Antidiabetika. In: Schwabe, U., Paffrath, D. (eds) Arzneiverordnungs-Report 2004. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-18513-7_12

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-18513-7_12

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-21359-8

  • Online ISBN: 978-3-642-18513-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation